Pharma Two B And Hepion Prepare For Final Stages of Merger After SEC Approval

Pharma Two B Ltd. is a late-stage clinical company working on an innovative treatment for Parkinson’s Disease called P2B001, and Hepion Pharmaceuticals  Inc. is a biopharmaceutical firm focused on treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Today, both the companies announced that the U.S. Securities and Exchange Commission (SEC) has approved their registration statement regarding their planned merger.

Initially proposed in July 2024, this merger has already received board approval from both companies and is anticipated to close in late 2024. The transaction is still subject to approval from both companies’ shareholders, regulatory clearances, listing of Pharma Two B’s shares on Nasdaq under the symbol “PHTB,” and other standard conditions.

Following the merger, the newly formed entity will operate under the name “Pharma Two B”. Hepion has scheduled a shareholder meeting on December 12, 2024, at 9:00 a.m. Eastern will approve the transaction via webcast at www.virtualshareholdermeeting.com/HEPA2024SM. Shareholders who owned shares as of November 6, 2024, are eligible to vote. Further details and voting instructions are provided in the proxy statement at http://www.sec.gov. With the SEC and is accessible on its website.

A.G.P./Alliance Global Partners is advising Hepion financially, Sullivan & Worcester LLP is serving as legal advisor to A.G.P with Sheppard, Mullin, Richter & Hampton LLP serving as its U.S. legal advisor. On the other hand, Lipa Meir & Co. is providing Israeli legal counsel to Hepion. Pharma Two B is financially advised by Laidlaw & Company (UK) Ltd., while Meitar Law Offices and Goodwin Procter LLP serve as legal advisors.